CN104547013A - Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid - Google Patents
Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid Download PDFInfo
- Publication number
- CN104547013A CN104547013A CN201410374799.0A CN201410374799A CN104547013A CN 104547013 A CN104547013 A CN 104547013A CN 201410374799 A CN201410374799 A CN 201410374799A CN 104547013 A CN104547013 A CN 104547013A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- oral liquid
- radix
- gastric mucosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 40
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 33
- 210000001156 gastric mucosa Anatomy 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 206010067125 Liver injury Diseases 0.000 title abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 230000002829 reductive effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 241000756943 Codonopsis Species 0.000 claims description 14
- 235000003935 Hippophae Nutrition 0.000 claims description 14
- 241000229143 Hippophae Species 0.000 claims description 14
- 241000180649 Panax notoginseng Species 0.000 claims description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 230000006837 decompression Effects 0.000 claims description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000004302 potassium sorbate Substances 0.000 claims description 4
- 229940069338 potassium sorbate Drugs 0.000 claims description 4
- 235000010241 potassium sorbate Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 abstract description 27
- 238000012360 testing method Methods 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 9
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 abstract description 8
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 abstract description 8
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 abstract description 7
- 235000008800 isorhamnetin Nutrition 0.000 abstract description 7
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 abstract description 6
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 abstract description 5
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 238000011835 investigation Methods 0.000 abstract description 2
- ILRCGYURZSFMEG-RKQHYHRCSA-N Salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RKQHYHRCSA-N 0.000 abstract 2
- 238000012546 transfer Methods 0.000 abstract 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- KSXPPAGQQYHJFU-UHFFFAOYSA-N Dendropanoxid Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2C1(O1)CCC1C2(C)C KSXPPAGQQYHJFU-UHFFFAOYSA-N 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000004526 pharmaceutical effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 15
- 208000037920 primary disease Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 8
- -1 calycosin glucoside Chemical class 0.000 description 8
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 229930182478 glucoside Natural products 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000002115 aflatoxin B1 Substances 0.000 description 4
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 4
- 229930020125 aflatoxin-B1 Natural products 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 230000002547 anomalous effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000010470 Ageusia Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008881 mucosal defense Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 2
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- LAWPHHZXTUPSDG-UHFFFAOYSA-N Astragaloside I Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C)C1OC(=O)C LAWPHHZXTUPSDG-UHFFFAOYSA-N 0.000 description 1
- KXHCYYSIAXMSPA-UHFFFAOYSA-N Astragaloside-I Chemical compound CC(=O)OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 KXHCYYSIAXMSPA-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- YSKVBPGQYRAUQO-UZSYLJJSSA-N Schottenol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 YSKVBPGQYRAUQO-UZSYLJJSSA-N 0.000 description 1
- YSKVBPGQYRAUQO-UHFFFAOYSA-N Schottenol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 YSKVBPGQYRAUQO-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- HJCCJZGOBHFQSX-UHFFFAOYSA-N cyclosieversioside B Natural products CC(CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1O)C2C(CC3(C)C4CC(O)C5C(C)(C)C(CCC56CC46CCC23C)OC7OCC(O)C(O)C7O)OC8OC(CO)C(O)C(O)C8O HJCCJZGOBHFQSX-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- YSKVBPGQYRAUQO-UBCZCFGNSA-N delta7 Stigmastenol Natural products O[C@@H]1C[C@@H]2[C@@](C)([C@@H]3C([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)=CC2)CC1 YSKVBPGQYRAUQO-UBCZCFGNSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940023492 oral liquid product Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229930183580 tangshenoside Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an oral liquid for treating gastric mucosa and liver injury and a preparation method of the oral liquid. The oral liquid for treating gastric mucosa and liver injury is characterized by being prepared from the following raw materials in parts by weight: 120 parts by weight of astragalus membranaceus, 120 parts by weight of codonopsis pilosula, 120 parts by weight of root of kudzu vine, 80 parts by weight of rhodiola rosea, 50 parts by weight of pseudo-ginseng and 50 parts by weight of sea-buckthorn. According to the oral liquid and the preparation method thereof disclosed by the invention, a three-factor three-level L9 (34) orthogonal test is carried out by taking water addition, decocting duration and decocting times as investigation factors, and variance analysis and confirmatory experiment are implemented by the six active ingredients for treating the disease as designing weight coefficients, so that the optimum decocting conditions are optimized. Through the preparation method, the transfer rates of the six active ingredients in the formula for treating the disease, namely astragaloside, campanulin, puerarin, rhodioloside, isorhamnetin and ginsenoside Re, are improved to be equal to or more than 90%, and significantly higher than the transfer rates through various existing extracting methods at home; and pharmaceutical effect is improved and cost is reduced.
Description
Technical field
The present invention relates to the field of Chinese medicines, particularly a kind ofly treat oral liquid of gastric mucosa and hepatic injury and preparation method thereof.
Background technology
Human body is in whole vital movement, and the source of material as vital movement energy of must absorbing nourishment from the external world, meets the needs of a series of metabolic activities such as human development, growth, reproduction, tissue repairing.Digestive system is the important system ensureing that human metabolism normally carries out, be responsible for picked-up and the digestion of food, us are made to obtain the nutrition such as saccharide fatty protein vitamin, the each organ coordination of digestion, the food absorbed from the external world is carried out the digestion of physical property, chemical, absorb its nutrient substance, and food debris is excreted.Stomach and liver belong to digestive system, and they have close contact.
In Chinese society population, there is the people of nearly 30% to have the gastric mucosa injury sex chromosome mosaicism such as various gastritis, have nearly 300,000,000 people through rough estimate total number of persons.Along with the fast development of modern society; competition; people are in huge operating pressure and stress for a long time; very easily cause the disorder of psychiatric system and hormonal system function; unsound dietary habit (eat raw by irregular, the cold drink of diet in addition; eating and drinking too much at one meal; smoking, to drink); and some disease all can cause gastric mucosa injury in various degree; make the natural protective barrier effect of coat of the stomach damaged, consider from the angle of prevention, first will protect gastric mucosa; make it reduce damage, and play the protective effect of gastric mucosa.
In addition, the whole world has more than 100 ten thousand patients to die from hepatopathy every year, and developing country's sickness rate is maximum.Wherein chemical liver injury is murderous one of the main reasons, and final final result is liver failure, liver cirrhosis and (or) primary hepatocarcinoma, causes great threat to human health.The hepatic injury of China in recent years caused by ethanol is in the trend risen year by year, and the hepatic injury recall rate in domestic population caused by ethanol is 4.34%.Ethanol has become the second largest cause of disease causing hepatic injury after viral hepatitis.Alcoholic liver injury can change into simple fatty liver, fat hepatitis, fatty liver fibrosis and fatty cirrhosis etc. further on clinical pathology.Alcoholic liver injury pathogenesis is illustrated not yet completely, also lacks curative effect medicine certainly.Greatly, commercial exchange, public relations dinner party is that the phenomenon of matchmaker is also more and more frequent with wine, and drinking amount and frequency are obviously on the rise for people from modern metropolitan cities life, cause pressure.Increasing people has been concerned about the health of self now, and the product of Antialcoholic liver-protecting also comes into one's own gradually, and therefore market potential is huge.
In sum, Chinese medicine gastric mucosa and hepatic injury being had to protective effect used in the market, still belongs to rare.
Summary of the invention
In order to overcome the deficiencies in the prior art, the invention provides and a kind ofly can effectively treat oral liquid of gastric mucosa and hepatic injury and preparation method thereof.
The technical solution adopted for the present invention to solve the technical problems is: a kind of oral liquid for the treatment of gastric mucosa and hepatic injury, it is characterized in that being made up of the raw material of following ratio of weight and number: the Radix Astragali 115 ~ 125 weight portion, Radix Codonopsis 115 ~ 125 weight portion, Radix Puerariae 115 ~ 125 weight portion, Radix Rhodiolae 75 ~ 85 weight portion, Radix Notoginseng 45 ~ 55 weight portion, Fructus Hippophae 45 ~ 55 weight portion.
Preferably, a kind of oral liquid for the treatment of gastric mucosa and hepatic injury, is made up of the raw material of following ratio of weight and number: the Radix Astragali 120 weight portion, Radix Codonopsis 120 weight portion, Radix Puerariae 120 weight portion, Radix Rhodiolae 80 weight portion, Radix Notoginseng 50 weight portion, Fructus Hippophae 50 weight portion.
A preparation method for the oral liquid of above-mentioned treatment gastric mucosa and hepatic injury, is characterized in that comprising the following steps of carrying out in order:
Step 1: by the Radix Astragali, Radix Codonopsis, Radix Puerariae, Radix Rhodiolae, Radix Notoginseng, the remove impurity respectively of Fructus Hippophae six kinds of raw material of Chinese medicine, clean, oven dry, then accurately weigh by corresponding ratio of weight and number.
Step 2: by load weighted raw material of Chinese medicine mixing decoction twice, all add 8 times for twice to the purified water of gross weight, all decoct 1.5 hours at every turn, twice decocting liquid filters respectively, merging filtrate, concentrating under reduced pressure (60 DEG C,-0.08MPa) be the clear paste of 1.10-1.15 (60 DEG C) to relative density, be placed to room temperature, add ethanol and reach 60% to alcohol content, leave standstill 24h, filter, filtrate decompression (60 DEG C,-0.08MPa) reclaim ethanol extremely without alcohol taste, add stevioside 0.4 weight portion, potassium sorbate 0.5 weight portion, stirring makes it dissolve, add purified water to 1000 weight portion, stir evenly, fill, sterilizing, the oral liquid of obtained described treatment gastric mucosa and hepatic injury.
The Radix Astragali is the dry root of leguminous plant Radix Astagali.Main containing astragaloside, astragaloside I, II, glucosan AG-1, AG-2, heteropolysaccharide AH-1, AH-2, calycosin, formononetin, kaempferide, Quercetin, isorhamnetin, calycosin glucoside and astragaloside are the active ingredient of its treatment primary disease.
Radix Codonopsis is the dry root of Campanulaceae Radix Codonopsis.Main containing alnulin acetas, suberone, normal-butyl allophanate, fructose, inulin, Δ 7-stigmastenol, stigmasterol ,-spinach sterol, methyl hexadecanoate, alnulin, Radix Codonopsis polysaccharide, choline, oleanolic acid, tangshenoside etc., the active ingredient for the treatment of primary disease is not clear so far.
Radix Puerariae is the dry root of legume pueraria lobata.Main containing puerarin, daiazi, daidzein, allantoin ,-sitosterol, daucosterol etc., the active ingredient for the treatment of primary disease is puerarin.
Radix Rhodiolae is the dry root welding technology of crassulaceae plants Radix Rhodiolae.Main containing saponin, organic acid etc., the active ingredient for the treatment of primary disease is rhodioside.
Radix Notoginseng is the dry root of panax araliaceae plant.Containing ginsenoside Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1, Rg2, Rg3, Rh1, F2, volatile oil, dencichine etc., the active ingredient for the treatment of primary disease is ginsenoside Re.
Fructus Hippophae is the dry mature fruit of Elaeangnaceae plant Fructus Hippophae.Main containing rutin, isorhamnetin and Quercetin etc., the active ingredient for the treatment of primary disease is isorhamnetin.
Research proves, the compositions of above Six-element Chinese medicine, solely containing Mutiple Targets micel, has a large amount of natural class active ingredient in micel.Have liver and fall the effect of enzymolysis fat, the accumulation of hepatic glycogen can be protected, can obviously prevent or reverse the hepatic injury caused by aflatoxin B1 (AFB1); To the hepatic injury caused by carbon tetrachloride (CC14), there is significant protective effect.Significantly can alleviate the centrilobular necrosis of hepatic parenchymal cells, hydropic degeneration and steatosis, total serum protein and albumin can be made obviously to increase, show that this product has liver protection effect.Said composition is evident in efficacy to taste-blindness rate, can stop ulcer, has inhibitory action to gastric acid secretion is hyperfunction, and the mechanism of action of its antiulcer and anti-gastric mucosa injury is main with to affect gastric mucosal defense function relevant.
Good effect of the present invention: drug prescription medication of the present invention is gentle, fully distinguishes disease, compared with existing Chinese medicine, has fully demonstrated the thought that traditional Chinese medicine theory combines with modern science basic research.The present invention just protects the liver nourishing the stomach entirely, improves immunity.Be specifically designed to and have protective effect to gastric mucosa and hepatic injury, clinical efficacy is remarkable, without any untoward reaction.In addition, in raw medicinal material, six kinds of active ingredient Astragaloside contents for the treatment of primary disease account for 0.06% of the Radix Astragali; Calycosin glucoside accounts for 0.08% of the Radix Astragali; Puerarin accounts for 3.51% of Radix Puerariae; Determination of Salidroside accounts for Radix Rhodiolae 0.92%; Isorhamnetin content accounts for Fructus Hippophae 0.18%; The content of ginsenoside Re accounts for 2.52% of Radix Notoginseng, current domestic prior art is lower to the rate of transform of these six kinds of active ingredients after extracting, all at about 40%-50%, and be 93.3% according to the astragaloside rate of transform in the obtained Chinese medicine composition of preparation method of the present invention, the calycosin glucoside rate of transform is 92.5%, the puerarin rate of transform is 94.2%, the rhodioside rate of transform is 95.7%, the isorhamnetin rate of transform is 94.4%, the rate of transform of ginsenoside Re is 91.3%, is significantly higher than existing method.
Detailed description of the invention
Below to a preferred embodiment of the present invention will be described in detail.
Embodiment 1
The preferred embodiment of the present invention 1 provides a kind of oral liquid for the treatment of gastric mucosa and hepatic injury, is made up of the raw material of following ratio of weight and number: the Radix Astragali 120 weight portion, Radix Codonopsis 120 weight portion, Radix Puerariae 120 weight portion, Radix Rhodiolae 80 weight portion, Radix Notoginseng 50 weight portion, Fructus Hippophae 50 weight portion.
A preparation method for the oral liquid of above-mentioned treatment gastric mucosa and hepatic injury, is characterized in that comprising the following steps of carrying out in order:
Step 1: by the Radix Astragali, Radix Codonopsis, Radix Puerariae, Radix Rhodiolae, Radix Notoginseng, the remove impurity respectively of Fructus Hippophae six kinds of raw material of Chinese medicine, clean, oven dry, then accurately weigh by corresponding ratio of weight and number.
Step 2: by load weighted raw material of Chinese medicine mixing decoction twice, all add 8 times for twice to the purified water of gross weight, all decoct 1.5 hours at every turn, twice decocting liquid filters respectively, merging filtrate, concentrating under reduced pressure (60 DEG C,-0.08MPa) be the clear paste of 1.10-1.15 (60 DEG C) to relative density, be placed to room temperature, add ethanol and reach 60% to alcohol content, leave standstill 24h, filter, filtrate decompression (60 DEG C,-0.08MPa) reclaim ethanol extremely without alcohol taste, add stevioside 0.4 weight portion, potassium sorbate 0.5 weight portion, stirring makes it dissolve, add purified water to 1000 weight portion, stir evenly, fill, sterilizing, the oral liquid of obtained described treatment gastric mucosa and hepatic injury.
Be 93.3% according to the astragaloside rate of transform in the Chinese medicine composition that above-mentioned preparation method is obtained, the calycosin glucoside rate of transform is 92.5%, the puerarin rate of transform is 94.2%, the rhodioside rate of transform is 95.7%, the isorhamnetin rate of transform is 94.4%, and the rate of transform of ginsenoside Re is 91.3%.
Method produced according to the present invention is made Chinese medicine oral liquid and is carried out the maximum resistance test of acute toxicity, and the day maximum tolerated dose of mouse stomach administration is 482 times of the clinical consumption per day of adult, under this dosage, do not observe any toxic reaction; Mouse marrow cell micro nuclear test and mouse inbred strain result are all feminine gender; Rat feeding test for 90 days, 120 times of oral dose behaviour consumption per day, indices detects and does not all observe ANOMALOUS VARIATIONS.
The Chinese medicine oral liquid that preparation method provided by the invention is made is 89.16% to chemical liver injury patient obvious effective rate, and effective percentage is 98.95%; Be 87.82% to the obvious effective rate of gastric mucosa injury patient, effective percentage is 95.51%, does not find obvious adverse reaction.Place 36 months under room temperature stock condition, every Testing index all meets statutory standards, and this product steady quality is described.
Disease prevention and control center of Henan Province check conclusion is: this oral liquid belongs to nontoxic level.This oral liquid Salmonella reversion test, mouse marrow cell micro nuclear test and mouse inbred strain result are negative.Rat feeding test for 90 days, when male and female Oral Administration in Rats high dose group is Coming-of-Age Day consumption 120 times, indices detects and does not all observe ANOMALOUS VARIATIONS.
Preparation method provided by the invention adopts orthogonal experiment, with six kinds of medical active active ingredients for evaluation index, design rational weight coefficient, and by variance analysis and confirmatory experiment, optimize best decocting process, to greatest extent the active ingredient for the treatment of primary disease in medical material is extracted out.
Because six kinds of active ingredients for the treatment of primary disease are all water solublity, therefore adopt water boiling and extraction the most suitable.With amount of water, decocting time and decoction number of times for investigating factor, carry out Three factors-levels L9 (3
4) orthogonal test, the foundation of active ingredient as design weight coefficient of primary disease is treated using six kinds.Two kinds of active ingredient astragalosides contained by the Radix Astragali and calycosin glucoside, its weight coefficient is all 0.1, and the weight coefficient of all the other four kinds of active ingredients is all 0.2; Be evaluation index by the percentage composition of above-mentioned six kinds of active ingredients respectively in each medical material of prescription decocted out, 8 times of to be each amount of water be medical material total amount that finishing screen selects best decocting process, decoct twice, each 1.5h.
Each sampling amount is all 1/10 of recipe quantity, and namely precision takes Radix Astragali 12g, Radix Codonopsis 12g, Radix Puerariae 12g, Radix Rhodiolae 8g, Radix Notoginseng 5g, Fructus Hippophae 5g, mixing.With amount of water (multiple for medical material gross weight), decocting time (h) and decoct number of times be investigation factor, decocting extraction is carried out by orthogonal test condition, decocting liquid filters, merging filtrate also reduces pressure (60 DEG C,-0.08MPa) be concentrated into the clear paste that relative density is 1.10-1.15 (60 DEG C), be placed to room temperature, add ethanol and reach 60% to alcohol content, leave standstill 24h, filter, filtrate decompression (60 DEG C ,-0.08MPa) reclaims ethanol to without alcohol taste, obtains medicinal liquid.Medicinal liquid adds purified water to 100g, stirs evenly, and filters, gets subsequent filtrate, to obtain final product.Precision measures subsequent filtrate, adopts the above-mentioned six kinds of active ingredient percentage compositions respectively in each medical material of prescription for the treatment of primary disease of high effective liquid chromatography for measuring respectively, the results are shown in Table 1,2.
Table 1 decocting extracts orthogonal test factor level table
Table 2 decocting extracts orthogonal test table
Decocting extracts the result of orthogonal test, comprehensive scoring method is adopted to carry out data analysis, six kinds of effective component contents for the treatment of primary disease, astragaloside and its weight coefficient of calycosin glucoside are respectively 0.1, and all the other four kinds active ingredient weight coefficients for the treatment of primary disease are all 0.2.Often kind of active ingredient scoring=this composition percentage composition/this composition percentage composition maximum × these composition weight coefficient × 100; The summation of six medical active component content scorings in comprehensive grading=this test of every test.
In table 2, extreme difference R shows each factor affects size to extraction effect, factor C > A > B; The size that each level of K value display affects extraction effect, factor A is K
2> K
3> K
1, factor B is K
2> K
3> K
1, factor C is K
2> K
3> K
1.From table 2 intuitive analysis, best decocting extraction conditions is A
2b
1c
2, namely add 8 times of water gagings, decoct 2 times, each 1.5h is best decocting process at every turn.Variance analysis is carried out in the impact of each factor on the medicinal active ingredient rate of transform, the results are shown in Table 3.
The variance analysis of table 3 decocting extraction effect
Variance analysis calculates:
M=S
2/ n-1 (mean square) F=M/M
by mistake(F value) M
by mistake=M
d
Look into F-distribution tables of critical values, obtain F
0.05(2,2)=19.00
F
0.01(2，2)＝99.00
Table 3 the results of analysis of variance shows, A, B, C factor affects, and all nonsignificances, illustrate that three factors on extraction rate all have equal influence, do not see which kind of factor particular importance, associative list 2 intuitive analysis, best decocting extraction conditions is A
2b
1c
2, namely add the water of 8 times amount at every turn, decoct 2 times, each 1.5h, verify that three batches the results are shown in Table 4. according to above-mentioned optimum condition
Table 4 decocting extracts confirmatory experiment result
Table 4 confirmatory experiment result is consistent with the orthogonal best decocting extraction conditions result of the test optimized, under these process conditions, six kinds of active ingredient rates of transform for the treatment of primary disease are all more than 90%, illustrate and adopt the decocting process preferably, compare with the like product circulated extensively in the market, its active ingredient rate of transform is all more than doubled, and this will play conclusive effect to the effect improving drug treatment disease.
Embodiment 2
Treat an oral liquid for gastric mucosa and hepatic injury, be made up of the raw material of following ratio of weight and number: Radix Astragali 120Kg, Radix Codonopsis 120Kg, Radix Puerariae 120Kg, Radix Rhodiolae 80Kg, Radix Notoginseng 50Kg, Fructus Hippophae 50Kg.
Its preparation method comprises the following steps of carrying out in order:
Step 1: by the Radix Astragali, Radix Codonopsis, Radix Puerariae, Radix Rhodiolae, Radix Notoginseng, the remove impurity respectively of Fructus Hippophae six kinds of raw material of Chinese medicine, clean, oven dry, then accurately weigh by corresponding ratio of weight and number.
Step 2: load weighted raw material of Chinese medicine is mixed, add purified water and decoct 2 times, each 1.5h, the mass ratio of each purified water and raw material is 8: 1, twice decocting liquid filters respectively, merging filtrate, concentrating under reduced pressure (60 DEG C,-0.08MPa) be the clear paste of 1.10-1.15 (60 DEG C) to relative density, be placed to room temperature, add ethanol and reach 60% to alcohol content, leave standstill 24h, filter, filtrate decompression (60 DEG C,-0.08MPa) reclaim ethanol extremely without alcohol taste, add stevioside 0.4Kg, potassium sorbate 0.5Kg, stirring makes it dissolve, add purified water to 1000L, stir evenly, fill, often prop up fill 15ml, fill 66600 altogether, yield rate is 99.9%, sterilizing, intermediate package often box-packed 10, fill 6660 boxes altogether, the every case of outer package fills 100 boxes.This oral liquid is brown liquid, and taste is sweet, micro-hardship.
Assay is carried out to this oral liquid product, and calculates its active ingredient rate of transform in table 5.
Table 5 this Chinese medicine composition effective component content and rate of transform
The rate of transform of above-mentioned each active ingredient is all more than 90%, and the current domestic like product rate of transform is all at about 30%-40%, and this extraction process is significantly higher than the now methodical active ingredient rate of transform, improves drug effect, reduces cost.
The described oral liquid pharmacy of the present invention, pharmacological toxicology and clinical trial:
The Chinese medicine oral liquid that the prescription provided according to the embodiment of the present invention 2 and preparation method are made carries out the maximum resistance test of acute toxicity in animal body, and be 482 times of the clinical consumption per day of adult to the day maximum tolerated dose of mouse stomach administration, this oral liquid belongs to nontoxic level; Mouse marrow cell micro nuclear test and mouse inbred strain result are all feminine gender; Rat feeds experiment in 90 days, and when male and female Oral Administration in Rats high dose group is 120 times of adult's oral dose, indices detects and all do not observe ANOMALOUS VARIATIONS.
Pharmacodynamic experiment proves, said composition has liver falls the effect of enzymolysis fat, can protect the accumulation of hepatic glycogen, can obviously prevent or reverse the hepatic injury caused by Aflatoxin B1 (AFB1); To the hepatic injury caused by carbon tetrachloride, there is significant protective effect.Significantly can alleviate the centrilobular necrosis of hepatic parenchymal cells, hydropic degeneration and steatosis, serum albumin and albumin can be made obviously to increase, show that this product has hepatoprotective effect.
Said composition is evident in efficacy to taste-blindness rate, can stop ulcer, has inhibitory action to gastric acid secretion is hyperfunction, and the mechanism of action of its antiulcer and anti-gastric mucosa injury is main with to affect gastric mucosal defense function relevant.
Long-term Clinical Observation result shows: the Chinese medicine oral liquid that the prescription provided according to the embodiment of the present invention 2 and preparation method are made is routine in 286 routine chemical liver injury patients effective 255 through long-term clinical application, obvious effective rate is 89.16%, effective 283 examples, effective percentage is 98.95%; Be applied to effective 274 examples of 312 routine gastric mucosa injury patients, obvious effective rate is 87.82%, and effective 298 examples, effective percentage is 95.51%, does not find obvious adverse reaction.
Place 36 months according under the Chinese medicine oral liquid room temperature storehouse storage requirement that composition of raw materials provided by the invention and preparation method are made, every Testing index all meets statutory standards and inner controlling standard of enterprise, and this product steady quality is described.
Above-describedly be only the preferred embodiments of the present invention; be understood that; the explanation of above embodiment just understands method of the present invention and core concept thereof for helping; the protection domain be not intended to limit the present invention; all any amendments, equivalent replacement etc. made within thought of the present invention and principle, all should be included within protection scope of the present invention.
Claims (4)
1. treat an oral liquid for gastric mucosa and hepatic injury, it is characterized in that: be made up of the raw material of following ratio of weight and number: the Radix Astragali 115 ~ 125 weight portion, Radix Codonopsis 115 ~ 125 weight portion, Radix Puerariae 115 ~ 125 weight portion, Radix Rhodiolae 75 ~ 85 weight portion, Radix Notoginseng 45 ~ 55 weight portion, Fructus Hippophae 45 ~ 55 weight portion.
2. a kind of oral liquid for the treatment of gastric mucosa and hepatic injury according to claim 1, is characterized in that: be made up of the raw material of following ratio of weight and number: the Radix Astragali 120 weight portion, Radix Codonopsis 120 weight portion, Radix Puerariae 120 weight portion, Radix Rhodiolae 80 weight portion, Radix Notoginseng 50 weight portion, Fructus Hippophae 50 weight portion.
3. a preparation method for the oral liquid for the treatment of gastric mucosa as claimed in claim 1 and hepatic injury, is characterized in that: comprise the following steps of carrying out in order:
Step 1: by the Radix Astragali, Radix Codonopsis, Radix Puerariae, Radix Rhodiolae, Radix Notoginseng, the remove impurity respectively of Fructus Hippophae six kinds of raw material of Chinese medicine, clean, oven dry, then accurately weigh by corresponding ratio of weight and number.
Step 2: by load weighted raw material of Chinese medicine mixing decoction twice, all add 8 times for twice to the purified water of gross weight, all decoct 1.5 hours at every turn, twice decocting liquid filters respectively, merging filtrate, concentrating under reduced pressure (60 DEG C,-0.08MPa) be the clear paste of 1.10-1.15 (60 DEG C) to relative density, be placed to room temperature, add ethanol and reach 60% to alcohol content, leave standstill 24h, filter, filtrate decompression (60 DEG C,-0.08MPa) reclaim ethanol extremely without alcohol taste, add stevioside 0.4 weight portion, potassium sorbate 0.5 weight portion, stirring makes it dissolve, add purified water to 1000 weight portion, stir evenly, fill, sterilizing, the oral liquid of obtained described treatment gastric mucosa and hepatic injury.
4. a kind of preparation method for the treatment of the oral liquid of gastric mucosa and hepatic injury according to claim 3, is characterized in that: described fill, often props up fill 15ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410374799.0A CN104547013A (en) | 2014-08-01 | 2014-08-01 | Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410374799.0A CN104547013A (en) | 2014-08-01 | 2014-08-01 | Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104547013A true CN104547013A (en) | 2015-04-29 |
Family
ID=53064785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410374799.0A Pending CN104547013A (en) | 2014-08-01 | 2014-08-01 | Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547013A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105707885A (en) * | 2016-02-03 | 2016-06-29 | 聊城大学 | Health product with liver repairing function and preparation method |
| CN108114015A (en) * | 2017-12-29 | 2018-06-05 | 吉林农业科技学院 | A kind of sponge gourd water asthma in children oral solution |
| CN112076251A (en) * | 2019-06-13 | 2020-12-15 | 陈奕帆 | Health tea for treating stomach diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5386M (en) * | 1966-02-02 | 1967-09-18 |
-
2014
- 2014-08-01 CN CN201410374799.0A patent/CN104547013A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5386M (en) * | 1966-02-02 | 1967-09-18 |
Non-Patent Citations (4)
| Title |
|---|
| 张宗林: "益气养阴方对CCl_4致小鼠肝损伤的保护作用", 《中医杂志》 * |
| 李垚等: "沙棘营养成分及作用的研究进展", 《中国初级卫生保健 营养与食品卫生》 * |
| 范青生等: "《保健食品注册申报实用指南》", 31 May 2006, 中国轻工业出版社 * |
| 谭永港等: "健胃汤对大鼠胃溃疡愈合质量及表皮生长因子受体表达的影响", 《中国基层医药》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105707885A (en) * | 2016-02-03 | 2016-06-29 | 聊城大学 | Health product with liver repairing function and preparation method |
| CN108114015A (en) * | 2017-12-29 | 2018-06-05 | 吉林农业科技学院 | A kind of sponge gourd water asthma in children oral solution |
| CN112076251A (en) * | 2019-06-13 | 2020-12-15 | 陈奕帆 | Health tea for treating stomach diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112245443A (en) | Composition of ginsenoside Rg3 and Rg5 and its anti-tumor medicine | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN107518260A (en) | A kind of food and preparation method thereof | |
| CN105343636A (en) | Dual-purpose medical and edible composition with blood fat reducing function and preparing method of dual-purpose medical and edible composition | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN104138526B (en) | A kind of root of three-nerved spicebush iron sheet ginseng granules agent | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN1935010B (en) | Health food for intensifying body immunological competence and improving memory function, and its preparing method | |
| TWI763970B (en) | Carob fruit composition and preparation method and application thereof | |
| EP1718167A1 (en) | Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN104547013A (en) | Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid | |
| CN102961414A (en) | Chinese herbal medicine raw stock and application thereof | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN106106907A (en) | A kind of by the liver-protecting tea beverage prepared by leaf of Camellia nitidissima Chi | |
| CN105795292A (en) | Drink containing corn stigma and ginseng and preparation method of drink | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN107136245A (en) | A kind of pure draft fat-reducing tea bag health food and preparation method thereof | |
| CN104474135A (en) | Pharmaceutical composition with auxiliary protection function of treating chemical liver injury | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN102764294A (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN104666823B (en) | A kind of regulation immunity, pharmaceutical composition of anti-aging and preparation method thereof | |
| CN107320569A (en) | A kind of flat fat chewable tablets and preparation method thereof | |
| CN113499366A (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| CN106309736A (en) | Anti-fatigue traditional Chinese medicine composition as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150429 |